HEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE
|
|
- Rhoda Karin Waters
- 5 years ago
- Views:
Transcription
1 HEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE DR DEAN T. GOROSKI, BCPS, CAPT, USPHS 2018 MPA WINTER CE AND SKI MEETING BIG SKY, MT JANUARY 6, 2018
2 DISCLOSURE Dr. Goroski has no actual, perceived, probable, suggested, potential, imaginary, conceptualized, likely, hopeful, aggravated, insinuated, or otherwise conflict of interest in relation to this program/presentation.
3 OBJECTIVES At the completion of this presentation, participants will be able to : Describe and differentiate the main diagnoses of heart failure Describe the pharmacologic goals of heart failure treatment and identify opportunities to optimize treatment Identify lifestyle changes to promote positive patient outcomes in heart failure management
4 OBJECTIVES Describe and differentiate the main diagnoses of heart failure Describe the pharmacologic goals of heart failure treatment and identify opportunities to optimize treatment Identify lifestyle changes to promote positive patient outcomes in heart failure management
5 CHRONIC HEART FAILURE (CHF) HF is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling(diastole) or ejection(systole) of blood. The cardinal manifestations of HF are dyspnea and fatiguewhich may limit exercise tolerance, and fluid retention-which may lead to pulmonary and/or splanchnic congestion and/or peripheral edema. Clyde W. Yancy et al. Circulation. 2013;128:e240-e327
6 HF DEFINITION IN BASIC TERMS Previously defined as Congestive Heart Failure Heart is unable to pump blood a sufficient volume of blood (cardiac output) to meet metabolic demands of the body Cardiac Output (CO) = Heart Rate (HR) x Stroke Volume (SV)
7 MORE DEFINITIONS Afterload--tension developed in the LV wall as systole occurs. Mainly determined by arterial blood pressure Preload--combination of pressure and volume in the left ventricle at the end of diastole (completely filled ventricle)
8 AND MORE DEFINITIONS Ejection Fraction (EF) The percentage of left ventricular blood volume ejected during systole(contraction) Normal is generally defined as 60-70% Right-sided and Left-sided HF Anatomical definitions only
9 HFPEF (DIASTOLIC DYSFUNCTION) Associated with an EF >40% Ventricle has diastolic stiffness Reduced compliance Unable to fill adequately Most common cause of HFpEF is hypertension Therapy aimed at heart rate & blood pressure control
10 HFREF (SYSTOLIC DYSFUNCTION) Low EF <40% Unable to eject enough blood to keep up with the metabolic demands of the body Ventricle has difficulty contracting ventricles become dilated congested with retained blood Most common cause of HFrEF MI (CAD)
11 PRESENTATION SIGNS Pulmonary rales Lower leg edema Jugular venous distention Increase BNP SYMPTOMS Dyspnea (on exertion) Orthopnea Paroxysmal nocturnal dyspnea Edema Fatigue Exercise intolerance
12 ASSOCIATED COMPLICATIONS IN HF MANAGEMENT Cardiac-AF, heart block, valvular abnormalities, CAD, anticlotting therapies Organ systems-renal failure, hepatic failure, respiratory disease Endocrine-DM, hypo/hyperthyroidism, endocrine tumors Other-obesity, nutrition, tobacco, toxins, emotional, economic, social, educational, financial, geographic, physical, transplant considerations, gout, etc..
13 CLASSIFICATION SYSTEMS NYHA -- functional status based on symptom severity I -- No symptoms with activity II -- Symptoms with usual activity III -- Symptoms with minimal activity IV -- Symptoms at rest ACC/ AHA -- based on disease evolution & progression A -- High risk for development but without of structural heart disease B Structural heart disease but without signs or symptoms of HF C Structural heart disease but with symptoms now or in past D -- Refractory, end-stage HF
14 GOALS OF HF MANAGEMENT Reduce morbidity/mortality rates Increase health-related quality of life measures and functional status Decrease health care associated costs
15 OBJECTIVES Describe and differentiate the main diagnoses of heart failure Describe the pharmacologic goals of heart failure treatment and identify opportunities to optimize treatment Identify lifestyle changes to promote positive patient outcomes in heart failure management
16 PATHOPHYSIOLOGY Damage heart is unable to meet demands Compensatory Mechanisms The body s response to decreased CO Intended to be short term response, detrimental in long term Maintain circulatory homeostasis after acute reductions in blood pressure or renal perfusion Neurohormonal Model Sympathetic nervous system (SNS) Renin-Angiotensin-Aldosterone System (RAAS)
17 SNS Causes tachycardia Tries to increase CO by increasing HR Causes increase in oxygen demand Eventually decreases filling time actually decreases SV Increases contractility Tries to increase CO by increasing SV Causes increase in oxygen demand
18 Direct remodeling of cardiac tissue RENIN ANGIOTENSIN ALDOSTERONE SYSTEM Increased fibrosis of cardiac tissue Angiotensin II receptors on the heart Increased fibrosis of endothelial & cardiac tissue Increases thirst drive Increases ADH release Increased Preload Increases water reabsorption from collecting duct Direct remodeling of cardiac tissue
19 CURRENT TREATMENTS LIVE LONGER MEDICATIONS Shown to improve mortality Beta-Blockers ACE-I/ARB Aldosterone Antagonists Hydralazine & isosorbide dinitrate *Sacubitril / valsartan FEEL BETTER MEDICATIONS No benefit on mortality Can help with hospitalizations Diuretics Loop Thiazide (Metolazone) Digoxin *Ivabradine
20 BETA BLOCKERS Recommended in stage B HFrEF and beyond, even if asymptomatic Can increase EF, especially if due to ischemic causes if compelling need for HR control (reduction of symptoms) Carvedilol, metoprolol SUCCINATE, bisoprolol only not a class effect for all beta blockers
21 BETA BLOCKERS Initiate therapy at low dose and advance, generally by doubling Q2-4 weeks, to predefined target doses Monitor closely for changes in vitals and symptoms (HF worsening, fatigue, bradycardia, hypotension) PEARL metoprolol succ. for hypotensive pts and/or concomitant respiratory disease PEARL carvedilol for hypertensive and/or DM
22 ACE INHIBITORS/ARBS Recommended in all stages and diagnoses of HF, unless contraindicated (angioedema, bilateral RAS, hyperkalemia) ACEIs generally considered over ARBs, unless development of kinin related cough (approx 10-20%) already on ARB therapy Data suggest class effect for ACEI, possible class effect for ARB
23 ACE INHIBITORS/ARBS Check renal function and electrolytes in 1-2 weeks after initiation, periodically thereafter Initiate therapy at low dose and advance, generally by doubling, to predefined target doses If target doses not tolerated, intermediate dosing acceptable PEARL losartan is the only antihypertensive capable of reducing uric acid levels ( mg/dl), so
24 ALDOSTERONE ANTAGONISTS Recommend in NYHA II-IV or AHA Stage C (stage B?) EF<35% After β blockers, and ACE-I titrated to max dose Of note, class II pts need CV hospitalization or high BNP After acute MI with EF<40% Useful in pts needing additional antihypertensive agents
25 ALDOSTERONE ANTAGONISTS Spironolactone initial dose mg daily, target 25mg daily Eplerenone initial dose 25mg daily, target 50mg daily More selective, better tolerated Do not start if SCr > 2.5 in men, >2.0 in women, or GFR < 30, or if potassium is greater than 5.0 meq/l Recheck potassium and renal function 2-3 days after start, again at 7 days, and again with dose changes (including ACEI or ARB)
26 HYDRALAZINE/ISDN Recommended for pts of African descent with symptomatic HFrEF (NYHA III-IV or AHA Stage C) ADD ON therapy for patients already on optimal ACEI/ARB and B blocker Recommended in pts of any race with current or prior symptomatic HFrEF that cannot be given ACEI or ARB therapy DO NOT substitute hydralazine/isdn for ACEI or ARB
27 SACUBITRIL / VALSARTAN (ENTRESTO) Newest Class of Medications for HF treatment Angiotensin Receptor-Neprilysin Inhibitor (ARNI) combination Approved for treatment of HFrEF, currently being studied in HFpEF *2016 and 2017 Update: In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE-I or ARB, replacement with an ARNI is recommended to further reduce morbidity and mortality. (Used in place of ACEI or ARB) Target Dose is 97mg/103mg BID Initial 24mg/26mg BID in ACEI/ARB naïve 49mg/51mg BID previously on ACEI/ARB
28
29 ADDITIONAL INFO Precautions/ Contraindications Angioedema Contraindicated with those with history Hypotension Drugs that increase potassium Adverse Effects Hypotension Hyperkalemia Cough Dizziness Renal failure Angioedema
30
31 LOOP DIURETICS Furosemide, bumetanide and torsemide Bumetanide and torsemide better availability and BP effects Reduce symptoms and hospitalizations, but not mortality Recognized as a threshold medication (think of QD vs BID) Risks-hypotension, fluid depletion, azotemia, hypokalemia, hypomagnesemia, arrhythmia
32 LOOP DIURETICS Hypotensive effects predominant during threshold phase, less afterwards Can be used even with GFR < 15ml/min Can potentiate gout through serum concentration effects Long-term use can potentiate diuretic resistance with need to increase dose or add thiazide
33 THIAZIDE-LIKE DIURETIC Metolazone acts distal tubule in addition to mild effects in proximal tubule VERY potent diuresis in combination with loop Retains benefits even with GFR < 30ml/min CAUTION C-SO2-NH2 PEARL delayed onset, delayed persistence
34 THIAZIDE DIURETICS Hydrochlorothiazide and Chlorthalidone Effects in the distal tubule (after loop) Greater blood pressure effects and longer persistence than loop diuretics Remove more sodium from system than loops Beneficial in hypertensive patients with mild fluid retention Can potentiate gout by blocking uric acid excretion
35 DIURETIC SUMMARY Factors to consider for diuretic therapy Blood pressure Volume status-degree of challenge, fluid overload vs fluid depletion Electrolyte balance-chem panel 3-5 days after starting or changing therapy Response and compliance to therapy Gout, allergies, lifestyle, adherence, morbidity/mortality
36 DIGITALIS May be added to HFrEF patients with persistent symptoms despite optimized GDMT Digoxin + B blocker = better control of ventricular response, esp during exercise Goal serum levels of ng/ml Multiple drug interaction and toxicity concerns
37 IVABRADINE (CORLANOR) If (Funny) Channel Inhibitor in SA node Consider in those who have a high HR despite optimal treatment Reduce the risk of hospitalization in chronic HF with the following characteristics: Stable, symptomatic heart failure LVEF <35% Sinus rhythm with resting HR >70 bpm On maximum tolerated doses of BB or contraindication to BB therapy Initial dosing 5mg BID, target dose 10mg BID
38 Swedberg K etal. Lancet 2010;376: 880 NNT for all-cause hospital admission is 25 over 2 years Reduction in deaths due to HR over 2 years: NNT 50 BEAUTIFUL Trial
39 ADDITIONAL INFO Adverse Effects Bradycardia Atrial fibrillation (d/c in this instance) Phosphenes (visual brightness) Monitoring BP, HR and rhythm Dizziness/fatigue Cost approx. $375/month
40 OBJECTIVES Describe and differentiate the main diagnoses of heart failure Describe the pharmacologic goals of heart failure treatment and identify opportunities to optimize treatment Identify lifestyle changes to promote positive patient outcomes in heart failure management
41 MEDICATIONS TO AVOID Antiarrythmics (except amiodarone and dofetilide) Calcium channel blockers (except amlodipine) NSAIDS Thiazolidinediones Nutritional supplements (except Omega 3s) and hormonal supplements unless to replace true deficiency
42 LIFESTYLE MODIFICATIONS Dietary sodium considerations Self-assessment and management Obesity management Exercise End of life considerations
43 DIETARY SODIUM RECOMMENDATIONS Stage A and B HF take salt shaker off the table, avoid adding extra to cooking Stage C and D HF excessively low and high sodium intake associated with worse outcomes, restrict <3gm sodium daily Sodium intake generally > 4gm/day in general population Salt substitutes may contain potassium!!
44 DAILY SELF-ASSESSMENT AND SELF- MANAGEMENT Monitoring of blood pressure at home direct comparison of personal and clinic readings Daily weight assessment and planning morning weight and charting finding dry or goal weight pre-determined strategies for out-of-range
45 OBESITY MANAGEMENT?? Obesity considered BMI > 30 HF-lowest mortality and hospitalization rates seen in BMI Highest mortality cardiac cachexia > morbidly obese > normal > overweight > obese lowest Consider appropriate weight loss if indicated
46 EXERCISE Exercise training (or regular physical activity) is recommended as safe and effective for HF patients able to participate Regular walking is considered gold standard Cardiac rehabilitation can increase HRQOL, functional capacity, exercise duration and morbidity
47 END OF LIFE PLANNING My take medical treatments and guidelines focus on battling mortality to the end, but fail to address acceptance of mortality and finding peace in dying with dignity. Have the talk with patients and family Plan for advanced directives, DNR/DNI, final resting place, estate planning, etc. Five Wishes Document (excellent resource!!)
48 QUESTION 1 HF with Reduced Ejection Fraction (HFrEF)is now used to describe what type of HF? A. Systolic Heart Failure B. Diastolic Heart Failure C. Right-sided Heart Failure D. Broken-heart syndrome (Tatsukobu s) E. No idea
49 QUESTION 1 HF with Reduced Ejection Fraction (HFrEF)is now used to describe what type of HF? A. Systolic Heart Failure B. Diastolic Heart Failure C. Right-sided Heart Failure D. Broken-heart syndrome (Tatsukobu s) E. No idea
50 QUESTION 2 Which of the following medications has NOT been shown to decrease mortality in HFrEF? A. Carvedilol B. Spironolactone C. Furosemide D. Lisinopril
51 QUESTION 2 Which of the following medications has NOT been shown to decrease mortality in HFrEF? A. Carvedilol B. Spironolactone C. Furosemide D. Lisinopril
52 QUESTION 3 What home-monitoring technique is best to determine the efficacy of a diuretic regimen? A. Skin pinch technique B. Seeing how your pants fit C. Asking a friend if you look puffy D. Daily home weights
53 QUESTION 3 What home-monitoring technique is best to determine the efficacy of a diuretic regimen? A. Skin pinch technique B. Seeing how your pants fit C. Asking a friend if you look puffy D. Daily home weights
54 RECOGNITION OF PEERS Dr. Tracy K. Pettinger, Clinical Associate Professor, Idaho State University Thank you for allowing me to use content from your 2017 presentation at Northwest Pharmacy Conference!! Dr Timothy Murray, CAPT USPHS, BCPS-AQ Cardiology Thank you for years of mentorship and collaboration on our patients in the Indian Health Service!!
55 REFERENCES 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Available at: ACC/AHA/HFSA Focused Update on Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA 2013 Guidelines for the Management of Heart Failure. Available at full.pdf ACC/AHA Guidelines for the evaluation and management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Am J Cardiol May 19. Available at:
56 REFERENCES CONTINUED McMurray JJ, et al. Angiotension-neprilysin inhibitor versus enalapril in heart failure. N Engl J Med 2014; 371: Swedberg K, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: Fox, K et al. Ivabradine for patients with stable coronary artery diesase and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: Klein L, O Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol 2003; 91:18F- 40F.
57 QUESTIONS?? CAPT Dean T. Goroski Pharmacy Supervisor Crow/N. Cheyenne Hospital Crow Agency, MT
Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More informationOutline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationHeart Failure CTSHP Fall Seminar
Heart Failure CTSHP Fall Seminar Laurajo Ryan, PharmD, MSc, BCPS, CDE Pharmacist Learning Objectives Outline the pathophysiology of heart failure List triggers for decompensated heart failure Describe
More informationHeart Failure Pharmacotherapy An Update
Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationObjectives. Outline 4/3/2014
Jessica Litke PGY1 ISHP Spring Meeting April 12, 2014 Objectives Appreciate the significance of heart failure (HF) to a patient and to the health care system Understand 2013 ACCF/AHA guidelines for the
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationClinical Pearls Heart Failure Cardiology/New Drugs
Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration
ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication and Symptomatic HF despite ACEI/ARB and B-blocker therapy Bilateral renal artery stenosis Moderate/Severe
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationTowards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationSara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012
Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012 Disclosure: Dr. Weiss has no significant financial interest in any of the products or manufacturers mentioned.
More informationInitiating New Medications in the Management of Heart Failure
Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant
More informationCase 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?
Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationPre-discussion questions
Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationHEART FAILURE KEEPING YOUR PATIENT AT HOME
HEART FAILURE KEEPING YOUR PATIENT AT HOME SUZANNE FRAZIER MS, CRNP, NP-C, CHFN HEART FAILURE DISEASE MANAGEMENT COORDINATOR PENN STATE HERSHEY HEART & VASCULAR INSTITUTE IMPACT OF HEART FAILURE In 2010,
More informationHeart Failure Medications: Who Needs What Drug Now? Disclosures
Heart Failure Medications: Who Needs What Drug Now? Simon Jackson MD FRCPC MMedEd Professor of Medicine (Cardiology) Dalhousie 1 Disclosures Honoraria and educational grants from: Actelion (medications
More informationManagement of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA
Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA Declaration of potential conflict of interests Type of job or financial support Salary Ordinary funds Position in
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationReview Article. Pharmacotherapy of Heart Failure with Reduced LVEF. Sachin Mukhedkar, Ajit Bhagwat
Review Article Vidarbha Journal of Internal Medicine Volume 22 January 2017 Pharmacotherapy of Heart Failure with Reduced LVEF 1 2 Sachin Mukhedkar, Ajit Bhagwat ABSTRACT Heart failure with reduced ejection
More information